A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

Kimihiro Tanaka, Eriko Tokunaga, Nami Yamashita, Kenji Taketani, Sayuri Akiyoshi, Masaru Morita, Yoshihiko Maehara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: The aim of the current study was to explore the efficacy and safety of combination therapy using a luteinizing hormone-releasing hormone (LHRH) agonist plus an aromatase inhibitor (AI) as second-line therapy in premenopausal females with hormone receptor (HR)-positive recurrent or metastatic breast cancer (MBC). Methods: A retrospective analysis was conducted in patients registered in the breast cancer database of our institution between January 2001 and December 2012. The breast cancer database identified 14 premenopausal patients who had been treated with an LHRH agonist plus AI for HR-positive recurrent or MBC. Results: Fourteen patients with recurrent breast cancer (N = 10) or metastatic disease at primary diagnosis (N = 4) were included in the present study. All patients had previously been treated with an LHRH agonist plus tamoxifen. The clinical benefit rate was 71.4 % and the median TTP was 11 months (95 % confidence interval 1.7-20.3 months). One patient discontinued treatment because of liver dysfunction (grade 3). Conclusions: The combination of an LHRH agonist plus an AI is a treatment option for premenopausal females with HR-positive MBC that can prolong the chemotherapy-free interval and yield effective disease stabilization.

Original languageEnglish
Pages (from-to)1678-1684
Number of pages7
JournalSurgery today
Volume44
Issue number9
DOIs
Publication statusPublished - Sep 2014

Fingerprint

Aromatase Inhibitors
Gonadotropin-Releasing Hormone
Hormones
Breast Neoplasms
Therapeutics
Databases
Tamoxifen
Liver Diseases
Confidence Intervals
Safety
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer. / Tanaka, Kimihiro; Tokunaga, Eriko; Yamashita, Nami; Taketani, Kenji; Akiyoshi, Sayuri; Morita, Masaru; Maehara, Yoshihiko.

In: Surgery today, Vol. 44, No. 9, 09.2014, p. 1678-1684.

Research output: Contribution to journalArticle

Tanaka, Kimihiro ; Tokunaga, Eriko ; Yamashita, Nami ; Taketani, Kenji ; Akiyoshi, Sayuri ; Morita, Masaru ; Maehara, Yoshihiko. / A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer. In: Surgery today. 2014 ; Vol. 44, No. 9. pp. 1678-1684.
@article{0bf1f29e6b624b48a316ff94a007a266,
title = "A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer",
abstract = "Purpose: The aim of the current study was to explore the efficacy and safety of combination therapy using a luteinizing hormone-releasing hormone (LHRH) agonist plus an aromatase inhibitor (AI) as second-line therapy in premenopausal females with hormone receptor (HR)-positive recurrent or metastatic breast cancer (MBC). Methods: A retrospective analysis was conducted in patients registered in the breast cancer database of our institution between January 2001 and December 2012. The breast cancer database identified 14 premenopausal patients who had been treated with an LHRH agonist plus AI for HR-positive recurrent or MBC. Results: Fourteen patients with recurrent breast cancer (N = 10) or metastatic disease at primary diagnosis (N = 4) were included in the present study. All patients had previously been treated with an LHRH agonist plus tamoxifen. The clinical benefit rate was 71.4 {\%} and the median TTP was 11 months (95 {\%} confidence interval 1.7-20.3 months). One patient discontinued treatment because of liver dysfunction (grade 3). Conclusions: The combination of an LHRH agonist plus an AI is a treatment option for premenopausal females with HR-positive MBC that can prolong the chemotherapy-free interval and yield effective disease stabilization.",
author = "Kimihiro Tanaka and Eriko Tokunaga and Nami Yamashita and Kenji Taketani and Sayuri Akiyoshi and Masaru Morita and Yoshihiko Maehara",
year = "2014",
month = "9",
doi = "10.1007/s00595-013-0765-4",
language = "English",
volume = "44",
pages = "1678--1684",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "9",

}

TY - JOUR

T1 - A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

AU - Tanaka, Kimihiro

AU - Tokunaga, Eriko

AU - Yamashita, Nami

AU - Taketani, Kenji

AU - Akiyoshi, Sayuri

AU - Morita, Masaru

AU - Maehara, Yoshihiko

PY - 2014/9

Y1 - 2014/9

N2 - Purpose: The aim of the current study was to explore the efficacy and safety of combination therapy using a luteinizing hormone-releasing hormone (LHRH) agonist plus an aromatase inhibitor (AI) as second-line therapy in premenopausal females with hormone receptor (HR)-positive recurrent or metastatic breast cancer (MBC). Methods: A retrospective analysis was conducted in patients registered in the breast cancer database of our institution between January 2001 and December 2012. The breast cancer database identified 14 premenopausal patients who had been treated with an LHRH agonist plus AI for HR-positive recurrent or MBC. Results: Fourteen patients with recurrent breast cancer (N = 10) or metastatic disease at primary diagnosis (N = 4) were included in the present study. All patients had previously been treated with an LHRH agonist plus tamoxifen. The clinical benefit rate was 71.4 % and the median TTP was 11 months (95 % confidence interval 1.7-20.3 months). One patient discontinued treatment because of liver dysfunction (grade 3). Conclusions: The combination of an LHRH agonist plus an AI is a treatment option for premenopausal females with HR-positive MBC that can prolong the chemotherapy-free interval and yield effective disease stabilization.

AB - Purpose: The aim of the current study was to explore the efficacy and safety of combination therapy using a luteinizing hormone-releasing hormone (LHRH) agonist plus an aromatase inhibitor (AI) as second-line therapy in premenopausal females with hormone receptor (HR)-positive recurrent or metastatic breast cancer (MBC). Methods: A retrospective analysis was conducted in patients registered in the breast cancer database of our institution between January 2001 and December 2012. The breast cancer database identified 14 premenopausal patients who had been treated with an LHRH agonist plus AI for HR-positive recurrent or MBC. Results: Fourteen patients with recurrent breast cancer (N = 10) or metastatic disease at primary diagnosis (N = 4) were included in the present study. All patients had previously been treated with an LHRH agonist plus tamoxifen. The clinical benefit rate was 71.4 % and the median TTP was 11 months (95 % confidence interval 1.7-20.3 months). One patient discontinued treatment because of liver dysfunction (grade 3). Conclusions: The combination of an LHRH agonist plus an AI is a treatment option for premenopausal females with HR-positive MBC that can prolong the chemotherapy-free interval and yield effective disease stabilization.

UR - http://www.scopus.com/inward/record.url?scp=84906789786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906789786&partnerID=8YFLogxK

U2 - 10.1007/s00595-013-0765-4

DO - 10.1007/s00595-013-0765-4

M3 - Article

C2 - 24218007

AN - SCOPUS:84906789786

VL - 44

SP - 1678

EP - 1684

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 9

ER -